OP0171 A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, MULTICENTER, STUDY OF METHOTREXATE COMBINED WITH PEGLOTICASE IN PATIENTS WITH UNCONTROLLED GOUT

Autor: J. Botson, K. Saag, J. Peterson, N. Parikh, S. Ong, D. La, K. Obermeyer, B. Lamoreaux, S. Sainati, S. Grewal, A. Majjhoo, J. Tesser, M. E. Weinblatt
Rok vydání: 2022
Předmět:
Zdroj: Annals of the Rheumatic Diseases. 81:112.1-113
ISSN: 1468-2060
0003-4967
DOI: 10.1136/annrheumdis-2022-eular.2949
Popis: BackgroundPatients (pts) with gout refractory to oral urate-lowering therapy (ULT) have few treatment options. Pegloticase (pegylated uricase) lowers serum uric acid (sUA) in these pts,1 but response rates are limited by anti-drug antibodies (ADAs), which decrease urate-lowering efficacy and increase infusion reaction (IR) risk.2 Because methotrexate (MTX) is commonly used in RA and prevents ADA development against biologics, co-administering MTX with pegloticase in uncontrolled gout pts is of interest. A small open-label study of pegloticase+oral MTX suggested an increased efficacy rate,3 so a randomized controlled trial (RCT) was conducted to compare pegloticase with/without MTX immunomodulation.ObjectivesTo determine safety/efficacy of oral MTX as co-therapy with pegloticase for sustained urate-lowering response in a randomized placebo (PBO) controlled trial.MethodsPegloticase+MTX and pegloticase+PBO co-therapy were compared in uncontrolled gout pts (sUA≥7 mg/dL, ULT failure/intolerance, and ≥1 of the following: ≥1 tophus, ≥2 flares in past yr, chronic gouty arthritis). Primary endpoint was the proportion of Month 6 treatment responders (sUA2). Pts were randomized 2:1 to oral MTX (15 mg/wk) or PBO. Following a 4 wk MTX/PBO run-in, pegloticase was initiated (Day 1). Both pegloticase (biweekly 8 mg infusions) and MTX/PBO were administered over 52-wks (treatment period). Efficacy was examined in the intent-to-treat population (ITT, all randomized pts); safety (AEs, laboratory values) in the safety population (all pts receiving ≥1 dose blinded MTX/PBO). Treatment was discontinued if pre-infusion sUA >6 mg/dL for 2 consecutive visits Wk 2 or later.Results152 pts (88.8% male) were randomized at 42 sites; 100 to pegloticase+MTX, 52 to pegloticase+PBO. 4 MTX, 3 PBO pts discontinued before first pegloticase dose; 26 MTX, 30 PBO pts who received pegloticase discontinued treatment at or before Wk 24. The primary endpoint was met with a 6-month response rate of 71.0% (71/100) vs 38.5% (20/52) in the MTX vs PBO co-therapy groups (p2 wks after pegloticase infusion 3 (deemed unrelated to study drug by site investigator). MTX-associated AEs4 did not occur more frequently in the MTX group (Table 1).Table 1.Key efficacy and safety findings through Month 6 of treatment.Pegloticase+MTXPegloticase+PBOITT populationN=100N=52Age, yrs, mean±SD55.6±12.753.0±12.1Tophi at baseline, %74.0%78.8%sUA at baseline, mg/dL, mean±SD8.7±1.69.1±1.76-mo treatment responders (primary endpoint), %71.0%38.5%Safety populationN=96N=49≥1 Serious AE, %8.3%10.2%≥1 treatment-emergent AE, %81.3%95.9%Gout flare*66.7%69.4%IR*, anaphylaxis*3.1%, 1.0%30.6%, 0%Cardiac event*1.0%0%Infection/infestation†10.4%16.3%Gastrointestinal†9.4%16.3%Skin†7.3%12.2%Respiratory/thoracic†5.2%4.1%Blood/lymphatic†2.1%2.0%Renal/urinary†, hepatobiliary†2.1%, 0%2.0%, 2.0%*AE of special interest, †known MTX AEConclusionThis RCT demonstrated significantly higher rate of sustained urate-lowering response over 6 months in pts co-treated with pegloticase+MTX vs pegloticase+PBO. No new safety concerns were seen through Month 6 and IR incidence was markedly lower in patients co-administered MTX vs PBO.References[1]Sundy JS, et al. JAMA 2011;306:711-20[2]Lipsky PE, et al. Arthritis Res Ther 2014;16:R60[3]Botson JK, et al. J Rheumatol 2021;48:767-74[4]MTX package insertDisclosure of InterestsJohn Botson Speakers bureau: Horizon Therapeutics, Consultant of: Horizon Therapeutics, Grant/research support from: Horizon Therapeutics, Kenneth Saag Grant/research support from: Horizon Therapeutics, Alinea, Lg, Sobi., Jeff Peterson Grant/research support from: Horizon Therapeutics, Naval Parikh Grant/research support from: Horizon Therapeutics, Stephen Ong Grant/research support from: Horizon, Novo Nordisk, Sanofi, Lilly, NIH/Mount Sinai, Dan La Speakers bureau: Abbvie, Grant/research support from: Horizon Therapeutics, Katie Obermeyer Shareholder of: Horizon Therapeutics, Employee of: Horizon Therapeutics, Brian LaMoreaux Shareholder of: Horizon Therapeutics, Employee of: Horizon Therapeutics, Stephen Sainati Shareholder of: Horizon Therapeutics, Employee of: Horizon Therapeutics, Suneet Grewal Speakers bureau: Horizon Therapeutics, UCB, Glaxo Smith Kline, Grant/research support from: Horizon Therapeutics, Amar Majjhoo Speakers bureau: Abbvie, Amgen, BMS, Horizon Therapeutics, Jansen, Glaxo Smith Kline, Astra Zeneca, Grant/research support from: Horizon Therapeutics, John Tesser Grant/research support from: Horizon Therapeutics, Michael E. Weinblatt Consultant of: Horizon Therapeutics
Databáze: OpenAIRE
Externí odkaz: